Growth Hormone, Stimulation and Suppression Tests

General

Synonym/Acronym:
somatotropic hormone, somatotropin, GH, hGH.

Rationale
To assess pituitary function and evaluate the amount of secreted growth hormone (GH) to assist in diagnosing diseases such as giantism and dwarfism.

Patient Preparation
The patient should fast and avoid strenuous exercise for 12 hr before specimen collection for stimulation and suppression studies. Some medications may adversely interact with the inducer used for the test, e.g., amphetamine, dextroamphetamine, and methylphenidate interact with clonidine. The requesting health-care provider (HCP) should be aware of any potential interacting medications used in the studies and advise restrictions by medical direction. Protocols may vary depending on the type of induction used.

Normal Findings
Method: Immunoenzymatic assay.


Growth Hormone
Age Conventional Units SI Units (Conventional Units × 1)
0–6 yr 0.1–6.2 ng/mL 0.1–6.2 mcg/L
7–17 yr
Male 0.05–11 ng/mL 0.05–11 mcg/L
Female 0.05–17.3 ng/mL 0.05–17.3 mcg/L
Adult
Male 0.05–3 ng/mL 0.05–3 mcg/L
Female 0.05–8 ng/mL 0.05–8 mcg/L
Stimulation Tests
Rise above baseline Greater than 5 ng/mL Greater than 5 mcg/L
Peak response Greater than 10 ng/mL Greater than 10 mcg/L
Suppression Tests 0–2 ng/mL 0–2 mcg/L

Other Growth Factors That May Be Requested
Insulin-like growth factor 1 (IGF1)By Report—See Overview
Insulin-like growth factor binding protein-3 (IGFBP-3)By Report—See Overview

Critical Findings and Potential Interventions
N/A

There's more to see -- the rest of this topic is available only to subscribers.